# Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2

> **NCT03332355** · PHASE1 · TERMINATED · sponsor: **Vanquish Oncology, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Anaplastic Astrocytoma

## Interventions

- **DRUG:** PAC-1 Compound

## Key facts

- **NCT ID:** NCT03332355
- **Lead sponsor:** Vanquish Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2023-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03332355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03332355, "Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03332355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*